GlassScriptPhysician profile
Halina E Polek- Nowakowska
NPI 1861598658
$18,041.06
in general payments reported to CMS, 2019-2025
38 companies · $2,718 in 2025
The $2,718 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,154 · 2020: $1,486 · 2021: $2,147 · 2022: $3,373 · 2023: $3,172 · 2024: $2,990 · 2025: $2,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,880.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,605.00 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,871.21 | 2019-2025 | Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,146.62 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $1,111.75 | 2019-2025 | Livdelzi |
| Madrigal Pharmaceuticals | $1,014.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $983.80 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Ironwood Pharmaceuticals, INC | $730.22 | 2020-2024 | Linzess |
| Janssen Biotech, INC. | $698.33 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $569.78 | 2019-2022 | |
| Genzyme Corporation | $554.02 | 2022-2025 | |
| Ardelyx, INC. | $535.28 | 2022-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $463.05 | 2021-2023 | Arexvy |
| Phathom Pharmaceuticals, INC. | $316.85 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $305.78 | 2020-2025 | Sucraid, Sucraid |
| Celgene Corporation | $296.05 | 2021-2024 | Zeposia |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $291.55 | 2019-2024 | Recarbrio, Dificid, Zerbaxa |
| Allergan, INC. | $265.99 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $262.61 | 2024-2025 | Iqirvo |
| Lilly USA, LLC | $248.82 | 2023-2025 | Omvoh |
| Pfizer INC. | $248.07 | 2019-2023 | |
| Braintree Laboratories, INC. | $212.02 | 2019-2025 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $207.61 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $179.37 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.97 | 2019-2022 | |
| Shionogi INC | $128.16 | 2019 | |
| Mauna Kea Technologies, INC. | $126.22 | 2022 | |
| Paratek Pharmaceuticals, INC. | $78.27 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $72.59 | 2019 | |
| Genentech USA, INC. | $71.83 | 2019 | |
| Ferring Pharmaceuticals INC. | $63.26 | 2020-2023 | Rebyota |
| Romark Laboratories, Lc | $44.22 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $40.27 | 2019-2024 | Exparel, Iovera, Zilretta |
| Novo Nordisk INC | $38.06 | 2025 | Wegovy |
| Baxter Healthcare | $22.89 | 2023 | Hillrom - Life 2000 Ventilation System |
| Aimmune Therapeutics, INC. | $17.49 | 2025 | Zenpep |
| Valinor Pharma, LLC | $17.03 | 2024 | Movantik |
| Celltrion USA INC. | $13.82 | 2025 | Vegzelma |
| Circassia INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halina Polek- Nowakowska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.